Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10903773 | 0.87 | GAA (0.66) | GAAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL10904614 | 0.84 | GAA (0.71) | GAAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL10902964 | 0.84 | GAA (0.63) | GAAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL13483837 | 0.84 | ALDH1A1 (0.64) | GAAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL10899850 | 0.84 | KMT2A (0.65) | GAAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL5922732 | 0.82 | ALDH1A1 (0.62) | GAAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL10904261 | 0.81 | TSHR (0.67) | GAAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL10904126 | 0.81 | TSHR (0.60) | ALDH1A1TSHRKMT2AMEN1HPGD | |
| SCHEMBL10903800 | 0.81 | NPSR1 (0.68) | GAAALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL10904271 | 0.81 | GAA (0.58) | GAAALDH1A1TSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110695-B2 | Compounds and compositions containing silicon and/or other heteroatoms and/or metals and methods of making and using them | WELKER MARK E (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100056801-A1 | Compounds And Compositions Containing Silicon And/Or Other Heteroatoms And/Or Metals And Methods of Making And Using Them | WELKER MARK E | 2010-03-04 | — | — | US | disclosed |
| US-4596826-A | Anticonvulsants | EISAI CO., LTD. (JP) | 1986-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056801-A1 | Compounds And Compositions Containing Silicon And/Or Other Heteroatoms And/Or Metals And Methods of Making And Using Them | CA6, SOD1, CA1 | GAA 656/4885ALDH1A1 2774/4885TSHR 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.